Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan:128:69-76.
doi: 10.1016/j.earlhumdev.2018.10.010. Epub 2018 Dec 13.

Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age

Affiliations

Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age

Ludmila N Bakhireva et al. Early Hum Dev. 2019 Jan.

Abstract

Background: While use of prescription opioids and medication assisted therapy (MAT) for opioid use disorder in pregnancy, as well as the incidence of neonatal opioid withdrawal syndrome (NOWS) continue to rise, little is known about outcomes for children with NOWS beyond the newborn period.

Methods: We examined 1) prenatal MAT exposure vs. unexposed healthy controls [HC]; and 2) treatment for NOWS and NOWS severity on infant neurodevelopmental and behavioral outcomes at 5-8 months of age in 78 maternal-infant pairs from the ENRICH prospective cohort study. Data were obtained from 3 study visits: prenatal, delivery, and neurodevelopmental evaluation at 5-8 months of age. Neurodevelopmental outcomes included the Bayley Scales of Infant Development [BSID-III], caregiver questionnaires (Parenting Stress Index [PSI-SF], Infant Behavior Questionnaire [IBQ-R], Sensory Profile), and the experimental Still-Face Paradigm (SFP).

Results: No differences in the BSID-III, PSI-SF, or IBQ-R scores were observed between MAT and HC groups; however, MAT-exposed and HC infants differed with respect to SFP self-regulation (β = -18.9; p = 0.01) and Sensory Profile sensation seeking (OR = 4.87; 95% CI: 1.55; 15.30) after adjusting for covariates. No significant differences between Treated-for-NOWS vs. not-Treated-for-NOWS were observed. Shorter timing to NOWS treatment initiation was associated with higher Total Stress (β = -9.08; p = 0.035), while longer hospitalization was associated with higher Parent-child dysfunctional interaction (p = 0.018) on PSI-SF.

Conclusions: Our results provide additional evidence of little-to-no effect of MAT and pharmacological treatment of NOWS on infant neurodevelopmental and behavioral outcomes at 5-8 months of age. However, prolonged hospitalization might increase family psychosocial stress and requires further examination.

Keywords: Infant neurodevelopment; Medication-assisted treatment; Opioids; Parental stress; Pregnancy; Substance use disorder.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1:
Figure 1:. Flowchart of ENRICH Study Participants Included in the Analysis
*The most common reasons for disqualifications include disqualifying drug use among any study groups and being positive for alcohol biomarkers among HC group.

Similar articles

Cited by

References

    1. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF, Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women, Obstet Gynecol 123 (2014) 997–1002. - PMC - PubMed
    1. Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD, Incidence of Neonatal Abstinence Syndrome - 28 States, 1999–2013, MMWR. Morbidity and mortality weekly report. 65 (2016) 799–802. - PubMed
    1. Kaltenbach K, Berghella V, Finnegan L, Opioid dependence during pregnancy. Effects and management, Obstetrics and gynecology clinics of North America. 25 (1998) 139–51. - PubMed
    1. Lowe J, Qeadan F, Leeman L, Shrestha S, Stephen JM, Bakhireva LN, The effect of prenatal substance use and maternal contingent responsiveness on infant affect, Early human development. 115 (2017) 51–9. - PMC - PubMed
    1. Milliren CE, Gupta M, Graham DA, Melvin P, Jorina M, Ozonoff A, Hospital Variation in Neonatal Abstinence Syndrome Incidence, Treatment Modalities, Resource Use, and Costs Across Pediatric Hospitals in the United States, 2013 to 2016, Hospital pediatrics. 8 (2018) 15–20. - PubMed

Publication types

Substances